西班牙内战
癌症
医学
政治学
梅德林
精密医学
历史
数据科学
计算机科学
家庭医学
作者
Aditya Varnam Shreenivas,Adam Wahida,Razelle Kurzrock
标识
DOI:10.1038/s41392-026-02661-0
摘要
Recently, Sheng et al. published the groundbreaking RC48-CO16 trial 1 in the New England Journal of Medicine; it showed that the combination of disitamab vedotin and toripalimab significantly improved median progression free survival (PFS) (13.1 versus 6.5 months (hazard ratio 0.36, P < 0.001)) and overall survival (OS) (31.5 versus 16.9 months (hazard ratio 0.54, P < 0.001)) compared with standard-of-care chemotherapy in patients with treatment-naive HER2-expressing, unresectable, locally advanced or metastatic urothelial carcinoma. This regimen may bring about a paradigm shift in the first-line management of HER2-expressing urothelial cancer, and these results underscore a fundamental yet often overlooked tenet in oncology--the timing of effective treatment is crucial.
科研通智能强力驱动
Strongly Powered by AbleSci AI